Khan, S., Burt, D., Ralph, C., Hawkins, R., & Elkord, E. (2011). Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells. Clinical Immunology, 138(1), 85-96. https://doi.org/10.1016/j.clim.2010.09.011